



4146220

HAEMATOLOGY

BLOOD - CITRATE

FIBRINOGEN

Result	Range	Units
3.1	2.0 - 4.5	g/L



HAEMATOLOGY COMMENTS

Fibrinogen test performed by accredited laboratory NATA: 2133

BIOCHEMISTRY

BLOOD - SERUM

UEC (Renal)

Result	Range	Units
--------	-------	-------

Sodium

138 135 - 145

mmol/L



Potassium

4.1 3.5 - 5.2

mmol/L



Chloride

102 95 - 110

mmol/L



Bicarbonate

22 20 - 32

mmol/L



Anion Gap

18 *H 8 - 16

mmol/L



Urea

6.4 4.0 - 9.0

mmol/L



Creatinine (mmol/L)

0.07 0.06 - 0.13

mmol/L



Creatinine

75 60 - 110

umol/L



Estimated GFR

>90 > 90

ml/min/1.73m²



UEC Comment

ELEVATED ANION GAP:

An elevated anion gap indicates metabolic acidosis. In uncontrolled diabetes, there is an increase in ketoacids due to metabolism of ketones. In these conditions, bicarbonate concentrations decrease by acting as a buffer against the increased presence of acids (as a result of the underlying condition). The bicarbonate is consumed resulting in a high anion gap.

ESTIMATED GFR COMMENT:

eGFR (mL/min/1.73m²) is calculated by the laboratory using the CKD-EPI formula
eGFR > 90 mL/min/1.73 sq.m - Normal GFR

LIVER FUNCTION TESTS

Bilirubin (Total)

7 0 - 20


umol/L



ALP

100 30 - 110

units/L



GGT

38 5 - 50

units/L



ALT

27 10 - 50

units/L



AST

31 10 - 50

units/L



Protein - Total

71 60 - 80

g/L



Albumin

42 33 - 48

g/L



Globulin

29 26 - 39

g/L



Urate

0.420 0.20 - 0.50

mmol/L



Ferritin

218 30 - 400

ug/L



(*) Result outside normal reference range

(H) Result is above upper limit of reference range



P: 1300 688 522
E: info@nutripath.com.au

-.NICOLE CHESTER
HERB BAR
1/39 WAGAWN STREET
TUGUN QLD 4224

MARK TWIST
21-Dec-1964 **Male**

26/28 CASTELLO CIRCUIT
VARSITY LAKES QLD 4227

LAB ID : 4146220
UR NO. : 6392620
Collection Date : 22-Sep-2025
Received Date: 23-Sep-2025



4146220

Iron Studies Comment

FERRITIN COMMENT:

Serum ferritin levels >30 µg/L demonstrates healthy iron stores as long as co-existing inflammatory disease or hepatocellular damage are not present.



4146220


LIPIDS

Cholesterol	5.0	0.0 - 5.5	mmol/L
Triglycerides	1.7	0.0 - 2.0	mmol/L




LIPID STUDIES

HDL(Protective)	1.1	0.9 - 2.0	mmol/L
Non-HDL Cholesterol	3.92	< 4.0	mmol/L
LDL(Atherogenic)	3.2	0.0 - 3.4	mmol/L
Cholesterol/HDL Ratio	4.7		
LDL/HDL RATIO (Risk Factor)	2.9	0.0 - 3.6	
Trig/HDL Ratio	1.6	0.5 - 1.7	RATIO
Lipoprotein (a)	30.7	0.0 - 75.0	nmol/L




APOLIPOPROTEIN PROFILE

Apolipoprotein B	0.92	0.70 - 1.20	g/L
Apolipoprotein A-1	1.23	1.10 - 1.80	g/L
RATIO (APO B / APO A-1)	0.74	0.45 - 1.25	
High Sens CRP	4.97	0.00 - 5.00	mg/L




LIPOSCREEN LDL Subfractions2

Very Low Density Lipoprotein (VLDL)	0.9 *H	0.1 - 0.6	mmol/L
Intermediate Density Lipoprotein (IDL-1)	0.6	0.1 - 0.6	mmol/L
Intermediate Density Lipoprotein (IDL-2)	0.4	0.1 - 0.4	mmol/L
Intermediate Density Lipoprotein (IDL-3)	0.5	0.1 - 0.6	mmol/L
Low Density Lipoprotein (LDL-1)	0.64	0.10 - 1.50	mmol/L
Low Density Lipoprotein (LDL-2)	0.67	0.10 - 0.80	mmol/L
Low Density Lipoprotein (LDL-3)	0.31 *H	0.00 - 0.20	mmol/L
Low Density Lipoprotein (LDL-4)	0.03 *H	0.00 - 0.01	mmol/L
Low Density Lipoprotein (LDL-5)	0.00	0.00 - 0.01	mmol/L
Low Density Lipoprotein (LDL-6)	0.00	0.00 - 0.01	mmol/L
Low Density Lipoprotein (LDL-7)	0.00	0.00 - 0.01	mmol/L
Mean Particle Size	264.0 *L	> 268.0	Angstrom



TYPE B- ABNORMAL





MARK TWIST
21-Dec-1964 **Male**

26/28 CASTELLO CIRCUIT
VARSITY LAKES QLD 4227

P: 1300 688 522
E: info@nutripath.com.au

-.NICOLE CHESTER
HERB BAR
1/39 WAGAWN STREET
TUGUN QLD 4224

LAB ID : 4146220
UR NO. : 6392620
Collection Date : 22-Sep-2025
Received Date: 23-Sep-2025



4146220

LIPOSCREEN Comments

RESULT INTERPRETATION

The Liposcreen LDL Subractions test provides a superior indicator for Coronary Artery Disease (CAD) risk than other conventionally available lipid profiles.

Many individuals with normal LDL and HDL cholesterol levels remain at risk from CAD as these conventional tests do not convey the detail of the CAD risk.

Liposcreen additionally quantifies the different subfractions.

Liposcreen clearly identifies a patient's LDL phenotype profile;

*This patient has a profile Not indicative of Type A, which is deemed **ABNORMAL**.*

This is due to the presence of elevated levels of small dense LDLs (LDL3 and LDL4).

Of note is the elevated VLDL, IDL B and C bands, which when elevated are also deemed highly atherogenic.

Also of note is the low LDL Mean Particle size of 264 Angstrom, which indicates the presence of LDLs of a size capable of penetrating the endothelial lining and causing the development of atheromatous plaques.

Lipoprotein Pattern Characteristics:

(Patient may have some or all of these present)

- | | |
|--------|--|
| Type A | Deemed a normal profile.
Predominance of large/buoyant (less atherogenic) LDL subclasses (LDL 1 and 2).
Mean Particle Size of > 263 Angstrom (A).
Elevated Cholesterol, Normal Triglycerides, Elevated Apo B |
| Type B | Deemed an ABNORMAL profile.
Predominance of small/dense (more atherogenic) LDL subclasses (LDL3, 4, 5, 6, 7).
Mean Particle Size of < 258 Angstrom (A).
Raised Cholesterol, Raised Triglycerides, Raised VLDL, Low HDLC
This profile is the designated atherogenic lipoprotein phenotype, consistent with an increased risk of CAD. It is also
It is also characteristically prevalent in insulin-resistant states such as Metabolic Syndrome and Type 2 Diabetes mellitus. |

Follow up Liposcreen testing, for this patient, is recommended in 3 months.



MARK TWIST
21-Dec-1964 **Male**

26/28 CASTELLO CIRCUIT
VARSITY LAKES QLD 4227

P: 1300 688 522
E: info@nutripath.com.au

-NICOLE CHESTER
HERB BAR
1/39 WAGAWN STREET
TUGUN QLD 4224

LAB ID : 4146220
UR NO. : 6392620
Collection Date : 22-Sep-2025
Received Date: 23-Sep-2025



4146220

Lipid Profile Comment

Target Levels for the general population and the National Vascular Disease Prevention Alliance (NVDPA) treatment target levels for high-risk people (known coronary heart and other arterial diseases, diabetes, chronic renal failure, Aboriginal and Torres Strait Islander peoples and familial hyperlipidaemic conditions) are:

	Tot. Cholesterol	LDL-Cholesterol	HDL-Cholesterol
General population:	<5.5 mmol/L	<3.0 mmol/L	M: >=1.0, F: >=1.0 mmol/L
At risk individuals:	<4.0 mmol/L	<2.5 mmol/L	

At risk:
Fasting Triglycerides: <2.0 mmol/L
Non-HDL Cholesterol: <3.3 mmol/L

National guidelines generally specify specific targets, refer to www.cvdcheck.org.au

ELEVATED TRIGLYCERIDES:
Increased levels are seen in primary hypertriglyceridaemic states, and secondary to Nephrotic syndrome, Hypothyroidism, Pancreatitis, Diabetes mellitus, Alcoholism, oral contraceptive use or corticosteroid medication.

GLUCOSE (FASTING)	5.3	3.0 - 5.4	mmol/L	
BLOOD - PLASMA				
Homocysteine	12.6	5.0 - 15.0	umol/L	

Tests ordered: APOS,BioPEI,CFee,eGFR,FATS,FERR,FGLU,FIB,GOG137,GOG257,GOG258,HCRP,HOMO,LFT,LIP,Lipo (a),LIPOSCRN2,UEC,URAT